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Background. Functional dyspepsia is a commonchronic disorder with non speciﬁc upper abdominalpain or discomfort.Diﬀerent
approaches with anti-secretory, spasmolytic, prokinetic and anti-inﬂammatory eﬀects and most preferably reduction of visceral
hypersensitivity seem logical. In this study, we compared the eﬀectiveness of the four most drugs used for treatment of dyspepsia
in children. Methods. 169 patients between 2 to 16 years old that 47.3% was male and 52.7% was female were enrolled in this
clinical trial study by the diagnosis of functional dyspepsia. Then for each patient one of the drugs; Omeprazole, Famotidine,
Ranitidine or Cimetidine was administered, for a period of4 weeks. Patients were followed after 2 and 6 weeks from the beginning
of the treatment. Results. The distribution of drugs between these patients were including; 21.9% with Cimetidine, 21.3% with
Famotidine, 30.8% with Omeperazole and 26% with Ranitidine that the proportion of patients with all symptoms relief were:
21.6% for Cimetidine, 44.4% for Famotidine, 53.8% for Omeprazole and 43.2% for Cimetidine (P = .024). In followups within 2
and6 weeks after beginning medical therapy, no side eﬀects due to drugs were seen. Conclusion. Ifa cure is deﬁned asall symptoms
relief after a period of 4 weeks treatment, our ﬁndings showed that Omeperazole are superior to Ranitidine, Famotidine, and
Cimetidine for management of functional dyspepsia.
1.Introduction
Functional dyspepsia (FD) is a very common cause of upper
gastrointestinal symptoms and discomfort [1]. FD has been
deﬁned as a functional gastrointestinal disorder (FGID)
characterized by persistent or recurrent pain or discomfort
centered in the upper abdomen that is not relieved by
defecation or associated with changes in stool characteristics
occurring at least once a week for at least 2 months in the
absence of organic diseases [2]. A diagnosis of FD can be
made in children mature enough to provide an accurate
history of pain that is present for at least a 12-week duration,
which need not be consecutive, in the preceding 12 months,
the recurrent discomfort is typically centered in the upper
abdomen (above the umbilicus), and there is no evidence of
organic disease (including at upper endoscopy). In addition,
there is no evidence that dyspepsia is exclusively relieved by
defecation or is associated with the onset of a change in
stool frequency or stool form. There are two presentations
of functional dyspepsia, which are ulcer-like dyspepsia and
dysmotility-like dyspepsia.
The low prevalence of organic disease found in dyspepsia
supports the use of reassurance and empiric therapy as
initial treatment, so the Rome committee recommends that
an upper gastrointestinal endoscopy should be performed
in the presence of dysphagia, persistence of symptoms
despite the use of acid reducing medications, or patients
with recurrent symptoms after discontinuing such medi-
cations [2]. Thus, diﬀerent approaches with antisecretory,
spasmolytic, prokinetic, and anti-inﬂammatory eﬀects, and,2 ISRN Pediatrics
most preferably, reduction of visceral hypersensitivity seem
logical. This could explain the variety of drugs which show
a positive symptomatic response [1], currently there is no
FDA-approved drug for treatment of FD [3].
Despite the scant evidence, anti-secretory agents are
frequently recommended in the treatment of patients with
a predominant complaint of pain while prokinetic agents
are frequently used for bloating and early satiety [4].
Patients’ symptoms that are severe enough to disrupt daily
activities will likely beneﬁt from pharmacologic therapy.
Such therapy should be individualized and directed toward
the predominant symptom [5].
For patients with predominant dyspepsia (discomfort
centered in the epigastrium, nausea, early satiety, postpran-
dial fullness, recurrent emesis), a short course of empiric
therapywithanH2-histamine receptorantagonistsorproton
pump inhibitors is acceptable. There are currently no
pediatric data to support the long-term beneﬁt of anti-
secretory therapy in patients with FGIDs [5].
The aim of this study is to compare the eﬀectiveness
of the commonly four most used drugs for treatment of
dyspepsia in children, including Omeprazole, Ranitidine,
Cimetidine, and Famotidine in a period of 4 weeks of
treatment.
2.PatientsandMethods
In this clinical trial study, 169 children between 2 and 16
years old were enrolled with the diagnosis of FD which
was made by a history of recurrent or persistent abdominal
pain and discomfort which was typically centered in the
upper abdomen for at least a 12-week duration without
any evidence of organic disorder. The other symptoms were
early satiety, postprandial abdominal ﬂoating or distention,
nausea and vomiting. Patients over 18 years old, and whom
their medical therapy could not be completed, and those
with symptoms including, fever over 38 centigrade degrees,
night sweating, weight loss more than 3kg during past
month, frequent vomiting, hematochezia or hematemesis,
severe localized pain, and dysphagia, were excluded from
this study. Then, for each patient, one of the acid suppres-
sant medications, Omeprazole, Famotidine, Ranitidine, or
Cimetidine, was administered, for a period of 4 weeks. The
drugsdosageused wasas follows: Cimetidine: 10mg/kg/dose
b.i.d., Ranitidine: 1-2mg/kg/dose b.i.d. (max: 300mg/24hr),
Famotidine: 1mg/kg/day b.i.d. (max: 40mg/24hr), and
Omeprazole: 1-2mg/kg/dayq.d (max: 40mg/24hr). Patients
were followed after 2 and 6 weeks from the beginning of the
treatment.
All the results, consisting of any probable side eﬀects
during the therapy and the eﬀectiveness of the medication
being used in treatment of the patients, were collected and
analyzed. Collected data and results were analyzed by SPSS
15 software. Standard deviation, mean, and distribution of
the results were also analyzed. Chi-square test and Students
t-test were also used to analyze the results. The signiﬁcant
P-value in this study was determined to be less than .05.
Table 1: Distribution of symptoms in all patients.
Symptom Distribution Percentage
Abdominal pain 169 100
Halitosis 129 76.3
Nausea 87 51.4
Anorexia 87 51.4
Nocturnal awakening 76 44.9
Early satiety 54 31.9
Vomiting 47 27.8
Heart burn 39 23.1
Chest pain 19 11.2
3.Results
There were 169 children with various dyspeptic symptoms
who participated in this study. 80 patients (43.7%) were
males and 89 patients (52.7%) were females. The mean age
of the patients was 7.4 ± 3.2 years (range, 2–16 years).
The mean durationof thedisease among thepatients was
15.9 ± 14.2 months (range, 3–60 months), and the mean of
their weight was 25.6 ± 11.7kg (range, 12–60kg). Ninety-
ninepatients(58.6%)hadapositivefamilyhistoryofFD,and
52 patients (30.8%) were passive smokers. In 108 patients
(63.9%), symptoms were related to food consumption;
occurrence of the symptoms in 35 patients (32.4%) was
before, in 55 patients (50.9%) was after, and in 18 patients
(16.7%) was both before and after food consumption. In
61 patients (36.1%), there was no relation between meal
consumption and symptoms.
Symptoms distributions are mentioned in Table 1.N o n e
of the patients had all the symptoms simultaneously.
Of these 169 children, 37 (21.9%) patients were treated
with Cimetidine, 36 (21.3%) with Famotidine, 44 (26%)
with Ranitidine, and 52 (30.8%) with Omeprazole. The
most common symptoms relieved regardless of type of
medication were nausea (86.2%), vomiting (80.8%), and
heart burn (79.5%). Abdominal pain was relieved in 63.9%.
The distribution and percentage of symptoms being relieved
regardless of the speciﬁc medication being administered are
shown in Table 2.
When diﬀerent medications were compared, abdominal
pain was improved in 45.9%, 65.9%, 66.7%, and 73.1%
of Cimetidine, Ranitidine, Famotidine, and Omeprazole
groups,respectively,thesediﬀerenceswere statisticallysignif-
icant (P<. 05). The distribution and percentage of symp-
toms being relieved in relation to the speciﬁc medication
being used are mentioned in Table 3.
The most inﬂuenced symptoms followed by medical
therapy in relation with speciﬁc medication were chest pain
in Famotidine group (100%), vomiting in Ranitidine group
(92.7%), nausea and vomiting in Cimetidine group (90%),
and nausea in Omeprazole group (87.8%), respectively. The
least inﬂuenced symptoms followed by medical therapy in
relation with speciﬁc medication was halitosis in all groups,
25.9%,44.8%,51.5%,and 52.5%in Cimetidine,Famotidine,
Ranitidine, and Omeprazole groups, respectively.ISRN Pediatrics 3
Table 2: Distribution and percentage of symptoms being relieved regardless of the speciﬁc medication.
Symptom Distribution before
treatment
Symptoms being
relieved
Percentage of symptoms
being relieved
Nausea 87 75 86.2
Vomiting 47 38 80.8
Heart burn 39 31 79.5
Nocturnal awakening 76 54 71
Chest pain 19 13 68.4
Early satiety 54 35 64.8
Abdominal pain 169 108 63.9
Anorexia 87 46 52.9
Halitosis 129 58 44.9
In 71 out of 169 patients (42%), all of the symptoms
were relieved, not considering the speciﬁc medication being
taken by them. When diﬀerent medications compared 8 of
37 patients who took Cimetidine cured completely (21.6%),
this cure rate in other groups were 43.2% (19 out of 44)
in Ranitidine, 44.4% (16 out of 36) in Famotidine, and
53.8% (28 out of 52) in Omeprazole group, diﬀerences were
statistically signiﬁcant (P = .024).
In the followups during 2 and 6 weeks after medical
therapy, no side eﬀects due to medical therapy were seen.
4.Discussion
FGIDs, including functional abdominal pain (FAP), are
among the most common conditions in children. A school-
basedstudyintheUnitedStatesshowed a38%overallweekly
prevalence of abdominal pain and persistence of symptoms
for more than 8 weeks in 24% of them. Children with
abdominal pain were found to miss more school than their
peers, and their parents frequently missed work to take care
of their children [6]. Some studies in children have shown
an association between chronic or recurrent abdominal
pain and higher depression and anxiety scores and poor
quality of life [6]. Despite its high frequency and signiﬁcant
impact on quality of life of children, there is only limited
evidence to support most treatments that are commonly
used to treat childhood FAP. Dietary recommendations
may be helpful for some patients with functional recurrent
abdominalpain ofchildhood [7].There are diﬀerentmedical
therapies with diﬀerent medications for treatment of this
disorder in children. In FD, the placebo response has
varied form 13–73% [8]. Patients’ symptoms that are severe
enough to disrupt daily activities will likely beneﬁt from
pharmacologic therapy [8]. Such therapy should be indi-
vidualized and directed toward the predominant symptom
[8]. Treatment modalities include medications, diet modi-
ﬁcation, herbal preparations, and behaviorally psychologic
interventions [9]. Enteric-coated peppermint-oil capsules,
believed to exert calcium channel blockade in smooth
muscle, were shown in a randomized, placebo-controlled
study to decrease the severity of abdominal pain, but not
other symptoms in pediatric patients with irritable bowel
syndrome [9]. Pharmacotherapy for treatment of FGIDs
consists of anticholinergic agents, tricyclic antidepressants,
serotonergic agents, selective serotonin reuptake inhibitors,
5-HT3 receptor antagonists, 5-HT4 receptor agonists, and
acid suppressive therapy [5]. For patients with predominant
dyspepsia (discomfort centered in the epigastrium, nausea,
early satiety, postprandial fullness, recurrent emesis), a short
course of empiric therapy with H2-receptor antagonists
or proton pump inhibitors is acceptable [5]. Some meta-
analysis studies showed that H2-receptor antagonists did or
did not have a signiﬁcant therapeutic eﬀect in FD [10, 11].
A meta-analysis of randomized controlled clinical trials has
shown that there may be a beneﬁt in the use of H2-receptor
antagonists in patients suﬀering from FD [12]. In another
study, it was found that Famotidine was equally eﬀective as
placebo [6].
In a meta-analysis, proton pump inhibitors were
regarded as superior to H2-receptor antagonists and antacids
in patients with “noninvestigated” dyspepsia [13], H2-
receptor antagonists and antacids showed positive eﬀects in
approximately 40% of patients (which is in the range of
the placebo response rate) whereas proton pump inhibitors
response rates were signiﬁcantly higher, adding an additional
20% [1]. Intwo preliminary studiesofOmeprazole, a proton
pump inhibitor, for the treatment of nonulcer dyspepsia,
only 50% of the patients treated with Omeprazole had a
response, as compared with 25% of those receiving placebo
[14].Inadouble-blindrandomizedplacebo-controlledstudy
of 4 weeks of Lansoprazole (a proton pump inhibitor) for
the treatment of FD in Chinese patients, ﬁndings implicated
that proton pump inhibitors treatment was not superior to
placebo for the management of FD in Chinese patients [15].
Proton pump inhibitors especially improved the symptoms
of epigastric pain and heart burn [1]. Several studies in
the primary care setting have concluded that proton pump
i n h i b i t o r sa r em o r ee ﬀective than H2-receptor antagonists or
antacidsintreatingheartburnanddyspepticsymptoms[16].
Therefore, empiric acid suppression would seem to be the
favored management approach for the treatment of FD [17].
Since the various proton pump inhibitors are of equiv-
alent eﬃcacy and safety, the cost and acceptability of a
particular proton pump inhibitor preparation may be more
important when selecting among them than comparable
eﬃcacy [18].4 ISRN Pediatrics
Table 3: Distribution of symptoms being relieved in relation to speciﬁc medication.
Symptoms Patients Drug Patients before
treatment
Percentage
before treatment
Patients whom
their symptoms
relieved
Percentage of
whom their
symptoms relieved
P-value∗
Abdominal
pain 169
Cimetidine 37 21.9 17 45.9
<.05 Famotidine 36 21.3 24 66.7
Omeprazole 52 30.8 38 73.1
Ranitidine 44 26 29 65.9
Epigastric
pain 89
Cimetidine 21 23.6 6 28.6
<.05 Famotidine 19 21.3 13 68.4
Omeprazole 30 33.7 20 66.7
Ranitidine 19 21.3 13 68.4
Periumbilical
pain 95
Cimetidine 20 21 11 55
>.05 Famotidine 17 17.9 11 64
Omeprazole 31 32.6 23 74
Ranitidine 27 28.5 16 59
Nausea 87
Cimetidine 20 23 18 90
>.05 Famotidine 13 15 11 84
Omeprazole 33 38 29 87.8
Ranitidine 21 24 17 80.9
Vomiting 47
Cimetidine 10 21.3 9 90
>.05 Famotidine 8 17 6 75
Omeprazole 17 36.2 12 70.6
Ranitidine 12 25.5 11 91.7
Anorexia 87
Cimetidine 18 20.7 8 44.4
>.05 Famotidine 24 27.6 12 50
Omeprazole 24 27.6 13 54.2
Ranitidine 21 24 13 61.9
Early satiety 54
Cimetidine 15 27.8 10 66.7
>.05 Famotidine 12 22 6 50
Omeprazole 13 24 11 84.6
Ranitidine 14 25.6 8 57.1
Heart burn 39
Cimetidine 6 15.4 3 50
>.05 Famotidine 8 20.5 7 87.5
Omeprazole 19 48.7 16 54.2
Ranitidine 6 15.4 5 83.3
Chest pain 19
Cimetidine 5 26.3 2 40
>.05 Famotidine 2 10.5 2 100
Omeprazole 8 42 6 75
Ranitidine 4 21 3 75
Halitosis 129
Cimetidine 27 21 7 25.9
>.05 Famotidine 29 22.5 13 44.8
Omeprazole 40 31 21 52.5
Ranitidine 33 25.6 17 51.5
Nocturnal
awakening
76 Cimetidine 16 21 9 56.3
>.05 Famotidine 18 23.7 14 77.7
Omeprazole 24 31.6 18 75
Ranitidine 18 23.7 13 72.2
∗The P-value is indicative of comparison between various medications eﬀectiveness with each symptom relief.ISRN Pediatrics 5
In this study, we compared the eﬀectiveness of four
medications including Cimetidine, Famotidine, Ranitidine
(all of them H2-receptor antagonists), and Omeprazole (a
proton pump inhibitor), for treatment of children with
dyspeptic symptoms, to ﬁnd the best one for this reason.
S oi fac u r ei sd e ﬁ n e da sa l ls y m p t o m sr e l i e fa f t e rap e r i o d
of 4 weeks treatment, our analysis indicates that there is a
signiﬁcant diﬀerence between response rate and the speciﬁc
medication being used (P = .024), and it reveals that
the most eﬀective medication, when considering cure as all
symptoms being relieved, was Omeprazole with response
rate of 53.8% and then with Famotidine (44.4%), Ranitidine
(43.2%), and, at last, with Cimetidine (21.6%). Although
no signiﬁcant diﬀerence (P = .06) was found in abdominal
pain relief in relation with speciﬁc medication consumption,
but due to higher response to Omeprazole, it seems that
Omeprazole was better than others, and Cimetidine had
the least eﬀect. Also, there were no signiﬁcant diﬀerences
between other symptoms relief (P>. 05) and the speciﬁc
medication taken by the patients, except for epigastric pain
which responds signiﬁcantly (P = .018) to Famotidine and
Ranitidine with response rate of 68.4% then Omeprazole
with 66.7% and at last Cimetidine with 28.6%.
According to our results and the fact that no signiﬁcant
side eﬀects being detected, and also due to the fact that Ran-
itidine and Omeprazole were the most eﬀective medications
on only one of the symptoms (epigastric pain) comparing
with Omeprazole that had the best result on all symptoms
being relieved, it cannot be concluded that Ranitidine and
Famotidine have equal or better eﬀect in treatment of FD,
but, in fact, the best medical therapy for treatment of FD is
Omeprazole, or in another way Omeprazole is superior to
H2-receptor antagonists for treatment of FD.
At the end it is important to note that since 3 of 4
medications that we used in our study had approximately
an equivalent eﬃcacy and safety, the cost of a particular
medication may be more important, when selecting among
them, than comparable eﬃcacy.
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